There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike
In a year defined by application surges, more than 200 ANDAs were submitted in September, the last month of fiscal year 2017, likely to avoid paying a much higher application fee instituted Oct. 1.
You may also be interested in...
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.
Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.
ANDA Approvals Break Record, May Set New Normal
FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?